Breaking Finance News

Mallinckrodt plc (NYSE:MNK) target price lowered to $85.00, issued a report today by Mizuho Securities

Yesterday Mallinckrodt plc (NYSE:MNK) traded -9.10% lower at $52.42. The company’s 50-day moving average is $61.54 and its 200-day moving average is $66.60. The last stock close price is down -21.29% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 8,771,869 shares of the stock were exchanged, up from an average trading volume of 1,870,960

Mallinckrodt plc (NYSE:MNK) had its target price lowered to $85.00 by Mizuho Securities in a report released 11/30/2016. The new target price indicates a possible upside of 0.62% based on the company's last stock close price.

Previously on Thursday November 24, 2016, Mizuho Securities reported about Mallinckrodt plc (NYSE:MNK) lowered the target price from $89.00 to $87.00. At the time, this indicated a possible upside of 0.53%.

See Chart Below

Mallinckrodt plc (NYSE:MNK)

Mallinckrodt plc has a 52 week low of $50.90 and a 52 week high of $85.83 with a P/E ratio of 9.88 The company’s market cap is currently $0.

In addition to Mizuho Securities reporting its target price, a total of 15 firms have issued a report on the stock. The consensus target price is $88.67 with 6 firms rating the stock a strong buy, 7 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Mallinckrodt plc (NYSE:MNK)

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company's segments include Specialty Brands, Specialty Generics and Nuclear Imaging. Its Specialty Brands segment produces and markets branded pharmaceutical and biopharmaceutical products for autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies, and central nervous system drugs. Its Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its Nuclear Imaging segment manufactures and markets radiopharmaceuticals (nuclear medicine).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.